FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3196804933> ?p ?o ?g. }

• W3196804933 endingPage "e2122607" @default.
• W3196804933 startingPage "e2122607" @default.
• W3196804933 abstract "Delayed healing of diabetic foot ulcers (DFUs) is known to be caused by dysregulated M1/M2-type macrophages, and restoring the balance between these macrophage types plays a critical role in healing. However, drugs used to regulate M1/M2 macrophages have not yet been studied in large randomized clinical trials.To compare the topical application of ON101 cream with use of an absorbent dressing (Hydrofiber; ConvaTec Ltd) when treating DFUs.This multicenter, evaluator-blinded, phase 3 randomized clinical trial was performed in 21 clinical and medical centers across the US, China, and Taiwan from November 23, 2012, to May 11, 2020. Eligible patients with debrided DFUs of 1 to 25 cm2 present for at least 4 weeks and with Wagner grade 1 or 2 were randomized 1:1 to receive ON101 or control absorbent dressings.Twice-daily applications of ON101 or a absorbent dressing changed once daily or 2 to 3 times a week for 16 weeks, with a 12-week follow-up.The primary outcome was the incidence of complete healing, defined as complete re-epithelialization at 2 consecutive visits during the treatment period assessed on the full-analysis set (FAS) of all participants with postrandomization data collected. Safety outcomes included assessment of the incidences of adverse events, clinical laboratory values, and vital signs.In the FAS, 236 eligible patients (175 men [74.2%]; mean [SD] age, 57.0 [10.9] years; mean [SD] glycated hemoglobin level, 8.1% [1.6%]) with DFUs classified as Wagner grade 1 or 2 (mean [SD] ulcer area, 4.8 [4.4] cm2) were randomized to receive either the ON101 cream (n = 122) or the absorbent dressing (n = 114) for as long as 16 weeks. The incidence of complete healing in the FAS included 74 patients (60.7%) in the ON101 group and 40 (35.1%) in the comparator group during the 16-week treatment period (difference, 25.6 percentage points; odds ratio, 2.84; 95% CI, 1.66-4.84; P < .001). A total of 7 (5.7%) treatment-emergent adverse events occurred in the ON101 group vs 5 (4.4%) in the comparator group. No treatment-related serious adverse events occurred in the ON101 group vs 1 (0.9%) in the comparator group.In this multicenter randomized clinical trial, ON101 exhibited better healing efficacy than absorbent dressing alone in the treatment of DFUs and showed consistent efficacy among all patients, including those with DFU-related risk factors (glycated hemoglobin level, ≥9%; ulcer area, >5 cm2; and DFU duration, ≥6 months).ClinicalTrials.gov Identifier: NCT01898923." @default.
• W3196804933 created "2021-09-13" @default.
• W3196804933 creator A5004314954 @default.
• W3196804933 creator A5022256556 @default.
• W3196804933 creator A5028047670 @default.
• W3196804933 creator A5031909460 @default.
• W3196804933 creator A5035863523 @default.
• W3196804933 creator A5037055730 @default.
• W3196804933 creator A5040737430 @default.
• W3196804933 creator A5045755790 @default.
• W3196804933 creator A5054176068 @default.
• W3196804933 creator A5054488523 @default.
• W3196804933 creator A5058341164 @default.
• W3196804933 creator A5066613612 @default.
• W3196804933 creator A5066961855 @default.
• W3196804933 creator A5069560545 @default.
• W3196804933 creator A5069611208 @default.
• W3196804933 creator A5069942000 @default.
• W3196804933 creator A5072370779 @default.
• W3196804933 creator A5078704026 @default.
• W3196804933 creator A5084861589 @default.
• W3196804933 creator A5089124196 @default.
• W3196804933 date "2021-09-03" @default.
• W3196804933 modified "2023-10-14" @default.
• W3196804933 title "Effect of a Novel Macrophage-Regulating Drug on Wound Healing in Patients With Diabetic Foot Ulcers" @default.
• W3196804933 cites W1560874819 @default.
• W3196804933 cites W1952455177 @default.
• W3196804933 cites W1973668238 @default.
• W3196804933 cites W2039122752 @default.
• W3196804933 cites W2047254124 @default.
• W3196804933 cites W2049831352 @default.
• W3196804933 cites W2058834052 @default.
• W3196804933 cites W2060499368 @default.
• W3196804933 cites W2110231257 @default.
• W3196804933 cites W2170645958 @default.
• W3196804933 cites W2272599847 @default.
• W3196804933 cites W2331213461 @default.
• W3196804933 cites W2405936796 @default.
• W3196804933 cites W2479398291 @default.
• W3196804933 cites W2529792914 @default.
• W3196804933 cites W2790092059 @default.
• W3196804933 cites W2793801139 @default.
• W3196804933 cites W2883058578 @default.
• W3196804933 cites W2899844209 @default.
• W3196804933 cites W2904792089 @default.
• W3196804933 cites W2947377351 @default.
• W3196804933 cites W2993908729 @default.
• W3196804933 cites W2995249215 @default.
• W3196804933 cites W2998941565 @default.
• W3196804933 cites W3027372909 @default.
• W3196804933 cites W4234955526 @default.
• W3196804933 cites W4240797082 @default.
• W3196804933 cites W4249999102 @default.
• W3196804933 cites W2890626748 @default.
• W3196804933 doi "https://doi.org/10.1001/jamanetworkopen.2021.22607" @default.
• W3196804933 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8417758" @default.
• W3196804933 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34477854" @default.
• W3196804933 hasPublicationYear "2021" @default.
• W3196804933 type Work @default.
• W3196804933 sameAs 3196804933 @default.
• W3196804933 citedByCount "32" @default.
• W3196804933 countsByYear W31968049332022 @default.
• W3196804933 countsByYear W31968049332023 @default.
• W3196804933 crossrefType "journal-article" @default.
• W3196804933 hasAuthorship W3196804933A5004314954 @default.
• W3196804933 hasAuthorship W3196804933A5022256556 @default.
• W3196804933 hasAuthorship W3196804933A5028047670 @default.
• W3196804933 hasAuthorship W3196804933A5031909460 @default.
• W3196804933 hasAuthorship W3196804933A5035863523 @default.
• W3196804933 hasAuthorship W3196804933A5037055730 @default.
• W3196804933 hasAuthorship W3196804933A5040737430 @default.
• W3196804933 hasAuthorship W3196804933A5045755790 @default.
• W3196804933 hasAuthorship W3196804933A5054176068 @default.
• W3196804933 hasAuthorship W3196804933A5054488523 @default.
• W3196804933 hasAuthorship W3196804933A5058341164 @default.
• W3196804933 hasAuthorship W3196804933A5066613612 @default.
• W3196804933 hasAuthorship W3196804933A5066961855 @default.
• W3196804933 hasAuthorship W3196804933A5069560545 @default.
• W3196804933 hasAuthorship W3196804933A5069611208 @default.
• W3196804933 hasAuthorship W3196804933A5069942000 @default.
• W3196804933 hasAuthorship W3196804933A5072370779 @default.
• W3196804933 hasAuthorship W3196804933A5078704026 @default.
• W3196804933 hasAuthorship W3196804933A5084861589 @default.
• W3196804933 hasAuthorship W3196804933A5089124196 @default.
• W3196804933 hasBestOaLocation W31968049331 @default.
• W3196804933 hasConcept C115076146 @default.
• W3196804933 hasConcept C120665830 @default.
• W3196804933 hasConcept C121332964 @default.
• W3196804933 hasConcept C126322002 @default.
• W3196804933 hasConcept C134018914 @default.
• W3196804933 hasConcept C138885662 @default.
• W3196804933 hasConcept C141071460 @default.
• W3196804933 hasConcept C168563851 @default.
• W3196804933 hasConcept C197934379 @default.
• W3196804933 hasConcept C2777180221 @default.
• W3196804933 hasConcept C2777538456 @default.
• W3196804933 hasConcept C2777858829 @default.
• W3196804933 hasConcept C2780269544 @default.

• next